IgA血管炎肾炎高质量临床试验路径:多专业国际协作研讨会纪要
IgA血管炎肾炎(IgAV-N)缺乏高质量循证研究,治疗差异大且预后不佳。53名来自13个国家的多专业代表召开研讨会,共识认为成人与儿童在受累器官、病理生理、组织学特征及治疗反应上足够相似,但儿童自发改善更多、部分人群肾脏结局更差。会议提出以肾衰竭高风险患者为初始试验重点,并制定行动路径。
要点
- 成人与儿童IgAV-N在器官受累、病理生理、组织学及治疗反应上足够相似。
- 初始临床试验应以肾衰竭高风险患者为主要焦点。
- 试验设计需考虑年龄包容性、系统性疾病次要终点及患者报告结局。
核心结论
- 成人与儿童IgAV-N在受累器官、病理生理、组织学特征及可能治疗反应上足够相似,但儿童自发改善更多、部分人群肾脏结局更差。
- 初始临床试验应以肾衰竭高风险患者为主要焦点。
研究设计与样本
- 多专业协作研讨会,53名参会者来自13个国家,包括非专业参会者,32%为教授、19%为中年资医生。
- 采用预设目标提取关键主题并制定行动计划。
主要发现
- IgAV-N缺乏循证临床研究,导致治疗方式差异大且结局不理想。
- 成人与儿童IgAV-N在受累器官、病理生理、组织学特征及可能治疗反应上足够相似。
- 重要差异包括儿童自发改善更多以及部分人群肾脏结局更差。
关键数值与推荐
- 初始临床试验应以肾衰竭高风险患者为主要焦点。
- 重要考虑包括成人起病IgAV的诊断分类、观察性数据、与IgA肾病科学相似性的证据、年龄包容性试验设计、系统性疾病次要终点及患者报告结局。
临床怎么用
- 临床试验应优先纳入肾衰竭高风险IgAV-N患者。
- 试验设计可采用年龄包容性方法,并纳入系统性疾病次要终点与患者报告结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IgA vasculitis (IgAV) is an autoimmune disease that affects the small vessels of the skin, joints, gastrointestinal (GI) tract, and kidneys. In the long term, IgAV associated with nephritis (IgAV-N) can progress to kidney failure. Evidence-based clinical studies of IgAV-N are few, leading to huge variations in treatment approaches and suboptimal outcomes. The wealth of emerging efficacious treatments for IgA nephrology brings new opportunities to this disease. The aim of this report is to describe the proceedings of a multiprofessional collaborative workshop convened to identify the barriers to developing high quality evidence for patients with IgAV-N. A multiprofessional group consisting of 53 attendees from 13 countries met. The meeting was represented by a variety of professional backgrounds, including lay attendees, with different levels of expertise (32% professors and 19% midcareer doctors). Using predefined aims, key themes were extracted, and an action plan developed. Consensus was obtained that there is sufficient similarity between adults and children in terms of the organs involved, pathophysiology, histological features, and likely response to treatment. Important differences included the greater spontaneous improvement in children and worse kidney outcomes in some populations. It was agreed that patients at greatest risk of kidney failure should be the primary focus of initial clinical trials. Important considerations included the following: diagnostic classification for adult onset IgAV, observational data, evidence of scientific similarity to IgA nephropathy (IgAN), an age-inclusive approach to trial design, systemic disease secondary end points, and the inclusion of patient-reported outcomes. This manuscript communicates an expert-informed pathway to high-quality evidence for IgAV-N.
引用
- Oni L, Smith R, Ozen S, et al. A Pathway to High Quality Clinical Trials in IgA Vasculitis Nephritis: Meeting Proceedings From a Multiprofessional International Collaborative Workshop. Kidney Int Rep. 2025. PMID: 41568275. doi:10.1016/j.ekir.2025.103729
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。